Abstract
Background: Bleomycin induced pulmonary toxicity is clinically detected using diffusing lung capacity for carbon monoxide (DLCO) in Hodgkin's Lymphoma (HL) patients after chemotherapy.
Objective: To evaluate changes in DLCO in HL patients after ABVD chemotherapy.
Methods: Medical records of all adult HL patients treated with ABVD chemotherapy at a single center in Lahore, Pakistan during the entire calendar year 2012 were analyzed. Patients with pre-existing pulmonary dysfunction, history of thoracic surgery and smokers were excluded.
Results: Out of 179 patients, 93 (51.95%) patients had received both a pre- and post-chemotherapy DLCO. The mean percentage difference between pre- and post-chemotherapy values for DLCO (5.49%; 95% confidence interval [CI] 1.56%-9.43%) and for Hemoglobin-adjusted DLCO (8.24%; 95% CI 3.90%-12.57%) were statistically significant at p<0.01. After adjusting for age, a 1mg/m2 increase in dose of Bleomycin was significantly associated with 0.14% (95% CI: 0.03%-0.25%) decline in DLCO and 0.13% (95% CI: 0.10%-0.26%) decline in hemoglobin-adjusted DLCO from pretreatment value.
p-value | ||
Pre and post DLCO | 0.007 | |
Pre and post Hemoglobin adjusted DLCO | 0.001 | |
Pre and post alveolar volume adjusted DLCO | 0.001 | |
Pre and post Hemoglobin and alveolar volume adjusted DLCO | 0.001 |
Conclusions: Mild to moderate dysfunction in diffusion lung capacity is common after ABVD chemotherapy.
- Copyright ©ERS 2015